Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034
Patents and patent application provide additional coverage for company’s therapeutic for patients with advanced solid tumors
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that the U.S. Patent and Trademark Office has issued two new patents, No.10,792,251 (the ‘251 patent) and No. 10,837,018 (the ‘018 patent), and allowed U.S. patent application 14/907,430 (the ‘430 application), further strengthening the Company’s intellectual property position and coverage for the Company’s therapeutic product candidate, cavrotolimod.
The ‘018 patent and the ‘430 application, both titled, “Spherical Nucleic Acid-based Constructs as Immunostimulatory Agents for Prophylactic and Therapeutic Use,” covers nanoparticles with a corona of CpG oligonucleotides and their methods for treating cancer.
The ‘251 patent, jointly owned by the Company and Northwestern University, titled, “Liposomal Particles, Methods of Making Same and Uses Thereof,” is directed to liposomal nanoparticles with toll-like receptor 9 (TLR9) agonist oligonucleotides and methods for treating cancer.
“The two issued patents and the soon-to-be-issued patent demonstrate our commitment to developing cavrotolimod, which is currently in a Phase 2 clinical trial for the potential treatment of Merkel cell carcinoma and cutaneous squamous cell carcinoma,” said David Giljohann, Chief Executive Officer of Exicure. “We are pleased with cavrotolimod’s development to date and excited about its potential to address unmet need for patients living with these rare forms of skin cancers.”
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is in Chicago, IL and has an office in Cambridge, MA.
For more information, visit Exicure’s website at www.exicuretx.com.
Exicure Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact could be deemed forward looking including, but not limited to, statements regarding the company’s intellectual property portfolio. The forward-looking statements in this press release speak only as of the date of this press release, and the company undertakes no obligation to update these forward-looking statements. Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risks that the ongoing COVID-19 pandemic may disrupt the company’s business and/or the global healthcare system more severely than it has to date or more severely than anticipated, which may have the effect of impacting or delaying the company’s ongoing Phase 1b/2 clinical trial; unexpected costs, charges or expenses that reduce the company’s capital resources; the company’s preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many drug candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; risks that preliminary results from clinical trials are not necessarily predictive of future clinical trial results; and the ability of the company to protect its intellectual property rights. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the company’s Quarterly Report on Form 10-Q, as updated by the company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the company undertakes no duty to update this information, except as required by law.
Source: Exicure, Inc.